Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors

Listen to CLL experts Jeff Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: September 17, 2020

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the second in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: September 16, 2020

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the third in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: September 17, 2020